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1. Introduction
In Asian countries, ginseng has been used by both 
patients and healthy individuals to restore and en-
hance vital energy [1]. Many in vitro and in vivo 
studies and clinical trials have investigated the phar-
maceutical effects, efficacies, and active components 
of ginseng [2]. In addition, studies have proposed 
that ginseng reduces physical, chemical, and bio-
logical stress, while increasing general vitality and 
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immune function, including physical and mental 
capacity [3,4]. The chemical constituents of ginseng 
have been identified, and approximately 40 active 
ingredients, including ginsenosides, polyacetylenes, 
sesquiterpenes, polysaccharides, and peptidoglycans, 
have been isolated [5,6].
The expanding consumption of ginseng for vari-
ous health-related benefits raises critical concerns 
about its efficacy, safety, and drug interactions [7−
10]. Although ginseng has long been broadly used 
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in clinical settings in Asia, more rigorous scientific 
evaluation is required to establish appropriate clin-
ical use. Recently, evidence-based medicine and 
evidence-based complementary and alternative med-
icine have become important in evaluating clinical 
trials [11,12]. For example, two recent clinical stud-
ies demonstrated that ginseng has no effect on ex-
ercise performance, contradicting other data in the 
medical literature and experimental research sup-
porting the effect of ginseng on physical perfor-
mance [13,14].
Relatively well designed randomized controlled 
trials (RCTs) are increasingly being conducted to 
determine the clinical efficacy and safety of ginseng 
for patients with specific diseases or conditions. 
These studies provide the best evidence in clinical 
medicine. The objective of this systematic review 
was to aid in the proper use of ginseng by critically 
evaluating the evidence from RCTs on its efficacy 
and safety.
2. Materials and Methods
2.1. Data sources and selection
Systematic literature searches were conducted 
using the electronic literature databases MEDLINE 
[15], CINAHL [16], EMBASE [17], five Korean medi-
cal databases (Korean Studies Information [18], 
DBPIA [19], Korea Institute of Science and Technology 
Information [20], Korea-Med [21], and Research 
Information for Health [22]), four Chinese medical 
databases (China Academic Journal [23], Century 
Journal Project [24], China Doctor/Master Disser-
tation Full-Text [25], and China Proceedings of 
Conference Full-Text [26]), and the Cochrane Library 
[27] from its inception to March 2009.
Studies in each language were screened using the 
following inclusion criteria: (1) human subjects, (2) 
use of a control procedure, (3) subjects randomized 
among treatment conditions, and (4) monoprepa-
ration tests of Panax ginseng or P. quinquefolium. 
An initial assessment using the inclusion criteria was 
made by reading abstracts. Articles that appeared 
to meet the criteria were then read in full by two 
authors, who then discussed the articles and made 
the decision to include or exclude them.
2.2.  Data extraction and methodological 
quality assessment
Two authors extracted data from the articles using 
a standardized, predefined method that considered 
trial methods, study design, patient characteristics, 
type of ginseng, outcomes, and side effects. We used 
the Jadad scale to evaluate the quality of clinical 
trials [28]. Points were awarded depending on the 
description of randomization, double-blinding, and 
appropriate/inappropriate methods, including with-
drawals and dropouts. On a five-point scale, trials 
with three or more points were considered high 
quality. Discrepancies were settled through discus-
sions involving two authors.
2.3. Review process
The RCTs were heterogeneous with respect to gin-
seng species or variety, indications, dose, partici-
pant characteristics, and outcome measures. The 
outcomes of some studies, however, were poorly 
presented. Therefore, we decided not to pool the 
data statistically, but performed a qualitative review 
instead. We reviewed RCTs to formulate conclusions 
on the effectiveness of ginseng for the following 
indications: glucose metabolism, physical perform-
ance, sexual function, psychomotor function, cardiac 
function, pulmonary disease, and cerebrovascular 
function. This method consisted of four levels of 
evidence on the methodological quality and outcome 
of the studies [29,30] as follows: level 1, strong evi-
dence, from generally consistent findings of multi-
ple relevant, high-quality RCTs; level 2, moderate 
evidence, from generally consistent findings of one 
relevant, high-quality RCT and one or more rele-
vant, low-quality RCTs; level 3, limited evidence, 
from generally consistent findings of multiple rel-
evant, low-quality RCTs; and level 4, inconclusive 
evidence, from only one relevant, low-quality RCT, 
no relevant RCTs, or RCTs with conflicting results.
“Generally consistent” was defined as two-thirds 
or more of the studies having the same result (pos-
itive or negative), and “multiple” was defined as 
more than one.
3. Results
3.1. Final data analyzed
Our searches identified 411 potentially relevant 
studies, of which 57 trials met our inclusion criteria 
(Figure 1). The key data from all of the included 
RCTs are summarized in Tables 1−8 [13,14,31−85].
3.2.  Description of studies and 
clinical questions
Of the 57 trials, 16 originated in Canada, 10 were in 
the United States, 13 were in Korea, 8 were in the 
United Kingdom, 4 were in China, and 1 each was in 
Australia, Brazil, Israel, Italy, Poland, and Thailand.
The clinical variables investigated were as fol-
lows: assessment of the effect of ginseng on glucose 
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metabolism (12 trials), physical performance (9 tri-
als), psychomotor function (8 trials), sexual function 
(7 trials), cardiac function (6 trials), and pulmonary 
disease (6 trials). The remaining nine RCTs addressed 
cerebrovascular function or miscellaneous issues.
3.3. Drug and participant characteristics
The 57 trials used two species of ginseng or a mix-
ture of species as follows: P. ginseng (including red 
ginseng), 37 studies; P. quinquefolium, 15 studies; 
and multiple ginseng types, 5 studies. Trials in-
cluded used either ginseng powder or ginseng ex-
tract (concentrated). The dosage was from 1 g to 
9 g ginseng powder versus from 0.2 g to 1.125 g gin-
seng extract per day. Sixteen of the 57 trials were 
one time dosing trials. Seventeen of the 57 RCTs used 
commercially sold ginseng preparations, i.e., G115, 
Ginsana, COLD-fX, and CVT-E002, which were stan-
dardized and ginsenoside contents were verified. 
Other trials, however, supplied insufficient data 
about standardization.
The various trials included a total of 3471 par-
ticipants. Healthy volunteers participated in 33 RCTs, 
patients with erectile dysfunction participated in 
7 trials, patients with hypertension or heart disease 
participated in 5 trials, patients with respiratory 
disorders participated in 4 trials, patients with di-
abetes participated in 3 trials, and individuals who 
were senile participated in 2 trials. The other RCTs 
included patients with cerebrovascular disease, 
Alzheimer’s disease, or chronic fatigue symptoms. 
The median number of participants was 30 (range: 
8−481).
3.4. Methodological quality
Of the 57 RCTs, 40 trials were of high quality (≥ 3 
Jadad score points), and 17 were low-quality trials 
(< 3 Jadad score points).
3.5. Glucose metabolism
Twelve studies investigated the effects of ginseng 
on glucose metabolism [31−42]. The methodology 
of 11 of these studies was good, scoring three or 
more points on the Jadad scale. One study scored 
two points, indicating a low quality. Of the 11 
high-quality trials, eight had positive results [31,
33−35,39−42], two had negative results [37,38] 
and one yielded variable results [36]. The result of 
one low-quality study was negative [32]. There-
fore, there was strong evidence to suggest that gin-
seng shows pharmaceutical properties for glucose 
metabolism (level 1 of best-evidence synthesis). 
One study [36] showed different glucoregulatory 
effects by various ginsengs and it suggested that 
the ginsengs might have had dissimilar ginsenoside 
profiles.
3.6. Physical performance
The efficacy of ginseng on physical performance was 
evaluated in nine trials [13,14,43−49]. All nine trials 
used healthy volunteers, including athletes as well 
as sedentary men. The duration of ginseng use lasted 
from 1 to 8 weeks. Of the nine studies, eight scored 
more than three points on the Jadad scale, and one 
scored 2 points. All the eight high-quality studies 
yielded negative results [13,14,43,45−49]. There-
fore, ginseng was not shown to enhance physical 
performance with strong evidence (level 1 of best-
evidence synthesis).
3.7. Psychomotor function
Eight trials evaluated the efficacy of ginseng on 
psychomotor function using P. ginseng or red gin-
seng [50−57]. The methodology of five of the studies 
was good, with a Jadad score of more than three 
points; the other studies scored two points. These 
studies yielded six positive [50,51,53−55,57] and 
two negative findings [52,56], which indicated strong 
evidence (level 1) of efficacy.
3.8. Sexual function
Seven RCTs investigated the effects of ginseng 
on erectile dysfunction [58−64]. The methodology 
of six of these studies was poor, scoring less 
than three points on the Jadad scale. Only one 
study scored four points, indicating good quality. 
One high-quality trial revealed a negative result 
[62], and six low quality trials had positive results 
[58−61,63,64]. Therefore, there was moderate ev-
idence that ginseng has pharmaceutical properties 
in erectile dysfunction (level 2 of best-evidence 
synthesis).
Figure 1 Scheme of the data selection process.
Initial independent
references from all
databases (n = 411) 
Trials excluded (n = 333) 
Duplicated articles (n = 135) 
With other substances (n = 76) 
No full text (n = 40)
Not clinical studies (n = 36) 
Not related articles (n = 41) 
No abstract (n = 5)
Trials excluded (n = 21) 
With other substances (n = 14) 
Not placebo-controlled (n = 7)
Full-text articles with 
potential relevance
(n = 89) 
Met inclusion criteria
(n = 57) 
88 N.H. Lee, C.G. Son
Table 1 Glucose metabolism studies [31−42]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Vuksan et al [31] Crossover 39 pts with type 2 diabetes Q: Efficacy and safety of use for type 2 diabetes
2008 5 points Red ginseng  A: Improved plasma glucose and insulin regulation
Canada  6 g (12 wk) S: One case of hypoglycemia
Reay et al [32]  Crossover 57 healthy subjects Q: Glucoregulatory effects of single ginseng dose
2006 2 points P. ginseng ex. (G115) A: Poor glucoregulation
UK  0.2 or 0.4 g (1 time) S: Not described
Sievenpiper Crossover 19 healthy subjects Q: Glucoregulatory effects: preparation and
 et al [33] 4 points Steamed P. ginseng  dose-finding study
2006  2 g, 4 g, or 6 g (1 time) A: Good glucoregulation using 2 g rootlet
Canada   S: None
Reay et al [34]  Crossover 27 healthy subjects Q: Effects on blood glucose level and cognitive
2006 4 points P. ginseng ex. (G115)  performance
UK  0.2 g (1 time) A: Improved glucose level and enhanced
    cognitive performance
   S: Not described
Reay et al [35]  Crossover 30 healthy subjects Q: Glucoregulation and cognition improvement
2005 5 points P. ginseng ex. (G115) A: Good glucoregulation and cognitive function
UK  0.2 or 0.4 g (1 time) S: Not described
Sievenpiper  Crossover 12 healthy subjects Q: Glucoregulatory effects of multiple types of
 et al [36]  3 points 8 types of ginseng ex.  ginseng
2004  3 g (1 time) A: Variable effects according to ginsenoside
Canada    profile
   S: Not described
Sievenpiper  Crossover 22 healthy subjects Q: Glucoregulatory effects−acute dose escalation
 et al [37]  3 points P. ginseng  study
2003  1, 2, 3, 6, or 9 g (1 time) A: Null and opposing effects
Canada   S: Not described
Sievenpiper  Crossover 12 healthy subjects Q: Glucoregulatory effects of different batches
 et al [38] 3 points P. quinquefolium A: Poor glucoregulation (probably due to 
2003  6 g (1 time)  depressed ginsenoside)
Canada   S: Not described
Vuksan et al  Crossover 12 healthy subjects Q: Timing and dosing effect on postprandial
 [39]  3 points P. quinquefolium  glycemia
2001  1, 2, or 3 g (1 time) A: Good glucoregulation in a time-dependent
Canada    manner
   S: None
Vuksan et al [40] Crossover 10 healthy subjects Q: Glucoregulatory effects on healthy subjects
2000 3 points P. quinquefolium A: Good glucoregulation (irrespective of time, 
Canada  3, 6, or 9 g (1 time)  dose)
   S: None
Vuksan et al [41]  Crossover 10 pts with type-2 Q: Glucoregulatory effects on pts with diabetes
2000 3 points  diabetes A: Good glucoregulation (irrespective of time or
Canada  P. quinquefolium  dose)
  3, 6, or 9 g (1 time) S: None
Vuksan et al [42]  Crossover 10 healthy/9 pts with Q: Glucoregulatory effects on different groups
2000 3 points  diabetes A: Good glucoregulation of both participant groups
Canada  P. quinquefolium S: One case of mild insomnia
  3 g (1 time)
Pt = patient; ex = extract.
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3.9. Cardiac function
Six studies investigated the effects of ginseng on 
cardiac function or disease [65−70]. Three of the 
studies were of high quality, with a Jadad score of 
three or more points. Of the studies, four had pos-
itive results [67−70] and two had negative findings 
[65,66], indicating moderate evidence (level 2).
3.10. Pulmonary diseases
Six studies assessed the effects or safety of ginseng 
on pulmonary diseases [71−76]. Five studies were 
of high quality, scoring three or more points on the 
Jadad scale, and all five yielded positive findings 
[71−75]. Therefore, there is strong evidence (level 1) 
that ginseng is effective in pulmonary function.
3.11. Cerebrovascular function
Two studies investigated the effects of ginseng on 
cerebrovascular function [77,78]. One study [78] 
was of high quality, scoring four points, but the 
other was of low quality with a score of two points 
[77]. Both studies showed positive results indicating 
moderate evidence (level 2).
Table 2 Physical performance studies [13,14,43−49]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Yoon et al [43] Parallel 30 healthy subjects Q: Effect on aerobic, anaerobic performance,
2008 (3) Red ginseng  central and peripheral fatigue
Korea 3 points 3 g (8 wk) A: No significant effects
   S: Not described
Kulaputana et al Parallel 60 healthy sailors Q: Effects on exercise performance with lactate
 [13]  (2) P. ginseng  threshold
2007 4 points 3 g (8 wk) A: No significant effect
Thailand   S: Not described
Hsu et al [44] Crossover 13 healthy men Q: Effects on creatine kinase and lactate during
2005 2 points P. quinquefolium  endurance exercise
China  1.6 g (4 wk) A: Decreased creatine kinase, no change in other
    parameters
   S: Not described
Engels et al [14] Parallel 38 healthy subjects Q: Effects on heart rate recovery, secretory IgA
2003 (2) P. ginseng ex. (G115)  after exercise
USA 4 points 0.4 g (8 wk) A: No significant effect
   S: Not described
Engels et al [45] Parallel 24 healthy women Q: Effects on recovery from short, supramaximal
2001 (2) P. ginseng ex. (G115)  exercise
USA 4 points 0.4 g (8 wk) A: No significant effect
   S: One case of stomach discomfort 
Allen et al [46] Parallel 28 healthy subjects Q: Effects on peak aerobic exercise performance
1998 (2) P. ginseng ex. A: No significant effect
USA 4 points 0.2 g (3 wk) S: Two cases of mild diarrhea
Engels et al [47] Parallel 36 healthy men Q: Effects during graded maximal aerobic exercise
1997 (3) P. ginseng ex. (G115) A: No significant effect
USA 4 points 0.2 or 0.4 g (8 wk) S: Three cases of diarrhea in high-dosage group
Morris et al [48] Parallel 8 healthy subjects Q: Effects on physical response to intense exercise
1996 (3) P. quinquefolium ex. A: No significant effect
Canada 4 points 8 or 16 mg/kg (1 wk) S: Not described
Engels et al [49] Parallel 19 healthy female subjects Q: Effect on work performance and energy
1996 (2) P. ginseng ex.  metabolism
USA 3 points 0.2 g (8 wk) A: No significant effects
   S: Not described
Pt = patient; ex = extract.
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3.12. Miscellaneous
The following seven other RCTs were also evaluated: 
Studies on the biological response to physical ex-
ercise [79,80], investigations on the interaction of 
ginseng and warfarin [81,82], examining side effects 
of P. ginseng and P. quinquefolium [83], a study on 
the effect of ginseng on health-related quality of life 
(HRQOL) [84] and an examination of body temper-
ature changes after taking ginseng [85].
The trials investigating the effects of ginseng 
on physical training showed no significant effects 
[79,80]. P. quinquefolium has been shown to reduce 
the anticoagulant effect of warfarin [82], whereas 
P. ginseng has no interaction with warfarin [81]. The 
other two trials showed no specific side effects of 
ginseng and no alteration of superficial body temper-
ature by ginseng [83,85]. The HRQOL trial reported 
a positive effect of P. ginseng on the QOL [84].
3.13. Safety
Thirty of the 57 trials reported the presence or ab-
sence of adverse events: 16 reported some side ef-
fects, whereas 14 found no side effects during the 
trials. The 27 other trials did not address the topic. 
Some side effects were species-related. P. ginseng 
was associated with gastrointestinal problems rang-
ing from stomach discomfort and nausea to vomiting 
and diarrhea [45−47,67], red ginseng was associated 
Table 3 Psychomotor function studies [50−57]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Lee et al [50] Parallel  97 pts with AD Q: Effects on cognitive performance of AD patients
2008 (2) P. ginseng A: Significantly effective in the cognitive
Korea 2 points 4.5 g (12 wk)  performance of AD patients
   S:  Two cases of heat sense, one case of dizziness, 
nausea, anorexia, diarrhea, and headache
Heo et al [51] Parallel 61 pts with AD Q: Efficacy for the treatment of AD
2008 (3) Red ginseng  A: High dose group showed significant 
Korea 2 points 4.5 or 9 g (12 wk)  improvement in ADAS and CDR
   S:  Two cases of fever (low dose), two cases of 
nausea (high dose)
Sunram-Lea et al Crossover 30 healthy subjects Q: Effects on cognitive performance and mood
 [52]  5 points P. ginseng ex. (G115) A: No significant effect, except for “speed of
2005  0.4 g (1 time)  attention”
UK   S: Not described
Scholey &  Crossover 20 healthy subjects Q: Dose-dependent effect on cognitive function
 Kennedy [53] 4 points P. ginseng ex. (G115) A: Improved accuracy and time of responses
2002  0, 0.2, 0.4, or 0.6 g (1 time) S: Not described
UK
Kennedy et al Crossover 20 healthy subjects Q: Effects on modulation of cognition and mood
 [54]  4 points P. ginseng ex. (G115) A: Positively affected cognitive performance
2002  0.4 g (1 time) S: Not described
UK
Kennedy et al Crossover 20 healthy subjects Q: Effects on cognitive performance
 [55] 3 points P. ginseng ex. (G115) A: Affected cognition in time-/dose-dependent
2001  0.2, 0.4, or 0.6 g (1 time)  manner
UK   S: Not described
Cardinal &  Parallel  83 healthy subjects Q: Effects on mood
 Engels [56]  (3) P. ginseng ex. (G115) A: No significant effect
2001 4 points 0.2 or 0.4 g (8 wk) S: Not described
USA
Ziemba et al Parallel  15 healthy subjects Q: Effects on psychomotor performance
 [57] (2) P. ginseng ex. A: Improved psychomotor performance
1999 2 points 0.35 g (3 wk) S: Not described
Poland
Pt = patient; ex = extract; AD = Alzheimer’s disease; ADAS = Alzheimer’s Disease Assessment Scale; CDR = Clinical Dementia Scale.
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with gastric upset [59,61,63], with one case of 
hypoglycemia [31], and P. quinquefolium was as-
sociated with insomnia, headache, chest discom-
fort, and diarrhea [42,66,83], plus type 2 diabetes 
mellitus [73].
4. Discussion
As of March 2009, the electronic database MEDLINE 
contained more than 3400 papers on ginseng-related 
research. The majority of studies were conducted 
using animal and in vitro experiments. The first clin-
ical trial with ginseng, in 1981, investigated general 
well-being, reaction time, lung function, and gonadal 
hormones [86]. Most RCTs studying ginseng have 
been performed since the late 1990s. Randomized 
controlled trials provide the best evidence of ther-
apeutic efficacy, pharmaceutical effects, and the 
safety of drugs, including ginseng [87].
There are two major species of ginseng, i.e., 
P. ginseng (called Korean ginseng or Asian ginseng) 
and P. quinquefolius L. (called American ginseng) 
[88,89]. P. ginseng is found to have the main prop-
erties of a ginsenoside, polyacetylene, acid poly-
saccharide, anti-oxidative aromatic compound, 
and insulin-like acid peptides. The number of gin-
senoside types of P. ginseng (38 ginsenosides) is 
substantially greater than those types present in 
P. quinquefolium (19 ginsenosides) [90]. Red gin-
seng refers to the steamed and dried form of 
P. ginseng [91]. In the course of the steaming process, 
ginseng starch is gelatinized, causing an increase 
in saponin content [9]. Results of clinical research 
studies have demonstrated that P. ginseng may im-
prove psychological function, immune function, and 
conditions associated with diabetes [2]. The phar-
macological effects of American ginseng have been 
observed in the central nervous, cardiovascular, en-
docrine, and immune systems [6,82,92]. Traditionally, 
red ginseng has been used to restore and enhance 
normal well-being, and is often referred to as an 
adaptogenic [9]. Accordingly, the RCTs that we re-
viewed posed various questions, including those 
Table 4 Sexual function studies [58−64]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
de Andrade et al Parallel  60 subjects with ED Q: Effects on ED
 [58] (2) Red ginseng  A: Significantly improved IIEF-5 score
2007 2 points 3 g (12 wk) S: None
Brazil
Choi et al [59] Parallel  30 pts with ED Q: Effect on penile blood flow of patients with ED
2003 (2) Red ginseng  A: Significantly improved penile blood flow
Korea 2 points 1.8 g (4 wk) S: One case of gastric discomfort
Hong et al [60] Crossover 45 subjects with ED Q: Effects on ED
2002 2 points Red ginseng  A: Significantly improved IIEF-5 score and 
Korea  2.7 g (8 wk)  penile tip rigidity
   S: Not described
Choi & Choi [61] Parallel  50 pts with ED Q: Effect on ED
2001 (2) Red ginseng  A: Significantly effective for ED
Korea 1 points 1.8 g (8 wk) S: One case of gastric discomfort
Kim & Paick [62] Parallel  26 pts with mild impotence Q: Effect on vasculogenic impotence
1999 (2) Red ginseng  A: No significant effect except for sexual
Korea 4 points 2.7 g (12 wk)  satisfaction score
   S: Not described
Choi et al [63] Parallel  50 pts with ED Q: Effect on ED
1999 (2) Red ginseng  A: Significantly effective for ED
Korea 2 points 1.8 g (12 wk) S: Two cases of constipation, two cases of 
    gastric upset
Choi & Seong [64] Parallel  90 pts with ED Q: Effect on ED
1995 (3) Red ginseng  A: Significantly effective for ED
Korea 1 points 1.8 g (12 wk) S: Not described
Pt = patient; ex = extract; ED = erectile dysfunction; IIEF-5 = International Index of Erectile Function-5.
92 N.H. Lee, C.G. Son
pertaining to glucose metabolism, physical perform-
ance, sexual function, psychomotor function, cardiac 
function, pulmonary disease, and cerebrovascular 
function.
We found that ginseng has positive effects on all 
of these indications, except for physical perform-
ance. Strong evidence (level 1) indicates that gin-
seng improves glucose metabolism, psychomotor 
function, pulmonary disease, and cerebrovascular 
function. Notably, 8 of the 12 glucose metabolism 
RCTs showed positive results for healthy subjects 
or patients with diabetes mellitus. Numerous re-
ports from both human and animal studies support 
our review-based results. For example, ginseng 
has been shown to increase insulin production and 
reduce cell death in pancreatic beta-cells [93−95]. 
To our knowledge, this study is the first systematic 
review of RCTs on the antidiabetic effects of ginseng 
varieties.
Many animal model-based studies have demon-
strated the effects of ginseng, or its ginsenoside com-
ponents, on anti-neurodegeneration [96], learning, 
and memory in aged and/or brain-damaged rodents 
[97,98]. All six psychomotor RCTs used only P. ginseng, 
whereas all of the ginseng varieties were used in the 
glucose metabolism RCTs.
Half of the pulmonary disease RCTs investigated 
the preventive effect of ginseng on respiratory ill-
ness, and all produced positive evidence [72−74]. 
This finding is in accordance with experiments using 
animal models [99,100].
Two RCTs found effects on central neuronal 
injury, cerebral blood flow, or vascular reactivity 
[77,78]. This is currently a major medical issue world-
wide, because of the high incidence of cerebrovas-
cular conditions and their impact on patient QOL. 
RTCs examining sexual function and cardiac func-
tion yielded moderate evidence (level 2) of gin-
seng efficacy. A recent systematic review article 
suggested that the results of seven RCTs investi-
gating therapeutic efficacy in erectile dysfunction 
showed that red ginseng is effective in the treat-
ment of erectile dysfunction [101]. Although exper-
imental data suggest the potential use of ginseng 
for hypertension [102,103], two RCTs demonstrated 
no effect of ginseng on hypertension in our review 
[65,66].
Ginseng has long been believed to enhance well-
being as a representative tonic [104]. However, 
contrary to our expectation, strong evidence (level 
1) indicated that ginseng is no more effective 
than a placebo in enhancing physical performance. 
Table 5 Cardiac function studies [65−70]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Stavro et al [66] Crossover 52 hypertensive subjects Q: Effect on hypertension
2006 3 points P. quinquefolium A: No significant effect
Canada  3 g (12 wk) S: One case of diarrhea and one of headache 
Stavro et al [65] Crossover 16 hypertensive subjects Q: Effect on hypertension
2005 3 points P. quinquefolium A: No significant effect
Canada  3 g (12 wk) S: None
Caron et al [67] Parallel  30 healthy subjects Q: Effects on electrocardiograph
2002 (2) P. ginseng ex. (Ginsana) A: Increased QTc interval, decreased diastolic BP
USA 3 points 0.2 g (4 wk) S: One case of nausea and vomiting
Ding et al [68] Parallel  45 pts with class IV cardiac Q: Effect on congestive heart failure
1995 (3)  function A: Showed significant effect as safe adjuvant
China 2 points Red ginseng S: None
  6 g (15 d)
Zhan et al [70] Parallel  30 pts with mitral-valve Q: Effect on myocardial IRI
1994 (3)  disease A: Showed protective effect against IRI
China 2 points P. ginseng saponins S: Not described
  0.6 or 1.2 mg/kg (10 d)
Zhao [69] Parallel  481 pts with CHD Q: Effect on aging and angina pectoris due to CHD
1990 (2) P. ginseng saponins A: Alleviated aging symptoms and angina pectoris
China 2 points 0.15 g (8 wk) S: None
Pt = patient; ex = extract; BP = blood pressure; IRI = ischemia reperfusion injury; CHD = coronary heart disease; QTc = heart rate-
corrected QT.
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However, all of the RCTs investigating physical per-
formance used healthy volunteers or trained athle-
tes, not patients. One review article, however, noted 
positive results from a trial using elderly subjects 
and a high ginseng dose [105].
Our review found that ginseng RCTs addressed 
heterogeneous questions, even when classified into 
eight broad categories, including miscellaneous. 
Therefore, some trials provided insufficient data, 
and statistical pooling was neither possible nor 
Table 6 Pulmonary disease studies [71−76]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Vohra et al [71] Parallel  75 children with URTI Q: Safety and tolerability in the treatment of
2008 (3) P. quinquefolium ex.  pediatric URTI (phase-2 study)
Canada 5 points 9−26 or 4.5−13 mg/kg (3 d) A: Standard doses (9−26 mg/kg) are appropriate
    for phase 3
   S: No serious adverse events
McElhaney et al Parallel  43 elderly subjects Q: Effects on prevention of ARI
 [72] (2) P. quinquefolium ex.  A: Significantly reduced the risk and duration of ARI
2006 5 points  (COLD-fX) S: Nonspecific adverse effects
Canada  0.4 g (16 wk)
Predy et al [73] Parallel  323 subjects with Q: Effects on prevention of common colds
2005 (2)  history of colds A: Significantly reduced the risk of colds
Canada 5 points P. quinquefolium ex. S: Two cases of type-2 diabetes mellitus
  0.4 g (16 wk)
McElhaney et al Parallel  198 elderly subjects Q: Effects on prevention of ARI
 [74] (2) P. quinquefolium ex.  A: Effective at preventing ARI
2004 4 points  (CVT-E002) S: None
USA  0.4 g (8−12 wk)
Gross et al [75] Parallel  100 subjects with COPD Q: Effect on pulmonary function in pts. with COPD
2002 (2) P. ginseng ex.(G115) A: Improved pulmonary function in pts. with COPD
Israel 4 points 0.2 g (12 wk) S: None
Scaglione et al Parallel  75 pt with chronic Q: Effects on chronic bronchitis
 [76]  (2)  bronchitis A: Significantly effective in bacterial clearance
2001 2 points P. ginseng ex.(G115) S: Not described
Italy  0.2 g (9 d)
Pt = patient; ex = extract; URTI = upper respiratory tract infection; ARI = acute respiratory illness; COPD = chronic obstructive pul-
monary disease.
Table 7 Cerebrovascular function studies [77,78]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Jeong et al [77] Crossover 10 healthy men Q: Effects on cerebral blood flow and
2006 2 points P. ginseng/red ginseng/  cerebrovascular reactivity
Korea   fermented red ginseng ex. A: Enhanced cerebrovascular reactivity and
  0.5 g (1 time)  increased cerebral blood flow
    S: None
Kennedy et al Crossover 15 healthy subjects Q: Electroencephalograph effects of a single dose
 [78]  4 points P. ginseng ex. (G115)  of ginseng
2003  0.2 g (1 time) A: Directly modulated cerebroelectrical activity
UK   S: Not described
Pt = patient; ex = extract.
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informative. Because trials differed in ginseng vari-
ety, indications, dose, participant characteristics, 
and outcome measures, we performed a qualitative 
review and opted for a best-evidence synthesis. To 
maximize objectivity, we adopted the levels of evi-
dence used in the systematic reviews of Cochrane 
[28]. In these analyses, sound evidence is deduced 
only from higher-quality studies, which are less likely 
to be biased. In our review, trials with three or more 
Jadad points were considered to be high-quality 
studies. Of the total 57 RCTs, 17 were rated as being 
of low quality based on the Jadad scale. Low-quality 
trials are more likely to overestimate efficacy [106]. 
In our review, low-quality trials tended to show pos-
itive results, with 88.2% (15/17) reporting positive 
findings compared with 45.0% (18/40) in high-quality 
trials. Therefore, we did not conduct a meta-analysis, 
which provides a strong analysis of methodologically 
sound RCT studies [107].
Our study is the largest systematic review of 
RCT-derived evidence on the clinical efficacies of 
ginseng. However, our results have some limitations. 
First, there are insufficient quantitative RCTs of 
ginseng to provide strong evidence for answering 
many clinical questions. Second, the RCTs were too 
heterogeneous in terms of design quality, sample 
size, species, dose, and duration to draw clear 
indications. Third, despite an extensive literature 
search, we may have missed trials and not all trials 
may have been identified. Moreover, review stud-
ies have a publication bias, as negative RCT results 
tend to have a lower chance of publication.
The safety profile of ginseng is generally good. 
The exact incidence of adverse effects is unknown, 
but it appears to be low. Side effects were not cor-
related with subject characteristics, ginseng species, 
dose, or duration. Unfortunately, 47.4% of the in-
cluded RCTs did not investigate side effects.
Table 8 Miscellaneous [79−85]
Authors Design Pt characteristics Questions (Q)
Year (No. of arm) Drug Answers (A)
Country Jadad score Dose (duration) Side effects (S)
Biondo et al [79] Crossover 14 healthy sedentary male Q: Effects on the immune response to moderate
2008 2 points P. quinquefolium ex.  exercise
Canada  1.125 g (5 wk) A: No significant effect
   S: Two cases of mild insomnia and hot flashes
Gaffney et al [80] Parallel  18 trained athletes Q: Effects of P. ginseng on steroidal hormone
2001 (3) P. ginseng  indices and immune variables during exercise
Australia 3 points 2 or 4 g (6 wk) A: No significant effect
   S: Not described
Lee et al [81] Parallel  34 pts with ischemic stroke Q: Interaction between warfarin and P. ginseng in
2008 (2) P. ginseng  ischemic stroke patients
Korea 3 points 1.5 g (2 wk) A: P. ginseng does not affect the pharmacological
    action of warfarin
   S: No serious side effects
Yuan et al [82] Parallel 20 healthy subjects Q: Interactions between ginseng and warfarin
2004 (2) P. quinquefolium A: Reduced anticoagulant effect of warfarin
USA 3 points 2 g (3 d) S: Not described
Seo et al [83] Parallel 320 healthy men Q: Side effects of P. ginseng and P. quinquefolium
2005 (5) P. ginseng/ A: No specific adverse effects of either
Korea 5 points  P. quinquefolium S: Two cases of chest discomfort in 
  3 g (4 wk)  P. quinquefolium group
Ellis & Reddy [84] Parallel 30 young subjects Q: Effects on HRQOL
2002 (2) P. ginseng ex. (Ginsana) A: Improved mental health and social functioning
USA 5 points 0.2 g (8 wk) S: One case of nausea and vomiting
Seo et al [85] Parallel 320 healthy men Q: Effect on superficial body temperature
2003 (5) P. ginseng/ A: No significant effect
Korea 5 points  P. quinquefolium S: Not described
  3 g (4 wk)
Pt = patient; ex = extract; HRQOL = health-related quality of life.
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As the use of herbal products is expanding world-
wide, more concerns are being raised about in-
teractions between herbs and conventional drugs, 
such as that of ginseng with phenelzine or warfarin 
[108−111]. Two RCTs in this review investigated in-
teractions between ginseng and warfarin [81,82]. 
This result is important for both physicians and pa-
tients, as anticoagulant drugs and ginseng products 
are often used together.
In conclusion, ginseng is beneficial for glucose 
control, central nervous system function, prevention 
of acute pulmonary disease, and cerebrovascular 
function, but not for enhancing physical perform-
ance. This review provides a compact assessment of 
ginseng use for people interested in ginseng prod-
ucts, as well as physicians. Additional well-designed, 
large-scale RCTs should be conducted in the future.
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